AstraZeneca Pharma India Limited has announced the appointment of Aditi Dayarus Mehta as Director – Oncology Business Unit, and Nitin Bindal as Director – Institutional Business & Public Channels, effective January 12, 2026. These appointments are based on the recommendation of the Nomination and Remuneration Committee and approval by the Board of Directors.
Leadership Expansion
AstraZeneca Pharma India Ltd. has strengthened its leadership team with the appointment of two new directors. Aditi Dayarus Mehta will take on the role of Director – Oncology Business Unit, and Nitin Bindal will serve as Director – Institutional Business & Public Channels. Both appointments are effective from January 12, 2026.
Aditi Dayarus Mehta’s Background
Ms. Mehta brings over 15 years of pharmaceutical experience. Before joining AstraZeneca, she held various positions at Pfizer India, including leading Pfizer’s Innovative Vaccine portfolio as Business Unit Director. She also worked as a Business Analyst at Bristol Myers Squibb. She holds a degree in Bachelor of Pharmacy from K.M. Kundnani College of Pharmacy, Mumbai.
Nitin Bindal’s Expertise
Mr. Bindal has over 17 years of experience in the pharmaceutical sector. His previous role was Business Unit Director Oncology & Haematology at Bristol Myers Squibb (BMS). He also held roles at Johnson & Johnson (J&J), Novartis, Wockhardt, and Smart Analyst. He holds a degree in Chemical Engineering from IIT Bombay and a management degree from UCLA Anderson School of Management.
Source: BSE
